Tero
Sign in
Companies›Biotech & health›Cytospire Therapeutics Limited
Download
Company intelligence · Prepared from public filings

Cytospire Therapeutics Limited

ACTIVENo. 14688240Incorporated 24 Feb 2023Altrinchamcell therapy R&D
Register data as of 27 Aug 2026
7 filings read · view all sources ↓
Watch this company
Raised, filed rounds
£30.4m
Priced rounds
6
Peak step-up
1.2x
Peak implied valuation
£41.7m
Last allotment
May 2026
Exhibit 1

Implied valuation at each priced allotment, 2023 to 2026

Implied post-money, GBP · price per share beneath each point · from SH01 filings
£11.7m£23.3m£35.0m£46.7m20232024202520262 May 2023: £12.4m implied post-money at £0.738 per share30 Nov 2023: £19.4m implied post-money at £0.738 per share3 Oct 2024: £22.4m implied post-money at £0.738 per share18 Mar 2026: £31.0m implied post-money at £0.865 per share25 Mar 2026: £38.3m implied post-money at £0.865 per share13 May 2026: £41.7m implied post-money at £0.865 per share£12.4m£0.738/sh£19.4m£0.738/sh£22.4m£0.738/sh£31.0m£0.865/sh£41.7m£0.865/sh
Source: Companies House, forms SH01 filed by Cytospire Therapeutics Limited; Tero analysis. Each point is one filed allotment; click any point to open the underlying filing.
Exhibit 2

Funding rounds, as filed

AllottedShare classPrice / shareRaisedImplied post-moneyStep vs priorSource
13 May 2026SERIES A£0.865£3.4m£41.7m· 1.0xSH01 ↗
25 Mar 2026SERIES A£0.865£7.3m£38.3m· 1.0xSH01 ↗
18 Mar 2026SERIES A£0.865£4.7m£31.0m▲ 1.2xSH01 ↗
3 Oct 2024SEED£0.738£3.0m£22.4m· 1.0xSH01 ↗
30 Nov 2023SEED£0.738£7.0m£19.4m· 1.0xSH01 ↗
2 May 2023SEED£0.738£5.0m£12.4mfirstSH01 ↗
Total, 6 priced rounds£30.4m
Source: Companies House filing history, company 14688240. Every row links to the filed document it was read from. Prices and share counts as filed; implied post-money is price per share times shares in issue after the allotment.
Similar companies on the register
Artios Pharma Limited
DNA damage response drug discovery
Grey Wolf Therapeutics Limited
immuno-oncology therapeutics
Draig Therapeutics Ltd
neuroscience therapeutics
Genomics Limited
genomic risk prediction
Methodology
Notes. Raised is the sum of shares allotted times price per share across priced allotments filed on form SH01. Peak step-up is the highest price per share divided by the first priced round. Implied post-money is price per share times shares in issue after the allotment: an approximation that ignores class rights and unexercised options. Allotments classified as option-scheme or nominal issues are excluded from the trajectory.
Primary documents
Every figure on this page is read from a document filed at Companies House and links to it. The full record is public: filing history of Cytospire Therapeutics Limited at Companies House ↗. Tero retains an archived copy of each parsed filing. Information, not investment advice.